Science & Medicine - Merck To Double Enrollment in AIDS Vaccine Trial After Promising Results Researchers conducting clinical trials of an AIDS vaccine made by pharmaceutical company Merck said they plan to double enrollment in the trials to 3,000 participants because results have exceeded their expectations, the Wall Street Journal reports. The trials are aimed at determining whether volunteers' imm www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=32714

2005-09-23

Science & Medicine - AIDS Vaccine Still Long Way Off; Researchers, Experts Still Optimistic Researchers are optimistic about a potential HIV/AIDS vaccine, even though none of the vaccines in development is likely to completely protect people from HIV transmission, participants at the XVI International AIDS Conference in Toronto said at a news conference Tuesday, Reuters reports. It is difficult to www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=39203

2006-08-16

Science & Medicine - Chinese Phase I Clinical Trial of HIV Vaccine Concluded Phase I of a three-phase clinical trial for an experimental HIV vaccine launched last year in Nanning, China, concluded on Sunday after researchers finished follow-up examinations of the 49 participants who received the vaccine Xinhua/People's Daily reports (Xinhua/People's Daily, 6/11). The trial participan www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=37864

2006-06-13

Media & Society - HIV/AIDS Vaccine Awareness Day May 18 is the 9th annual HIV/AIDS Vaccine Awareness Day. A listing of local and national HIV/AIDS Vaccine Awareness Day activities may be found here. AIDS Vaccine Clearing House In related news, the AIDS Vaccine Advocacy Coalition on Wednesday launched the AIDS Vaccine Clearing House, a source of HIV/AIDS www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=37338

2006-05-18

Science & Medicine - Italy AIDS Vaccine Ready for Human Trials A unique vaccine candidate developed by Italian scientists will soon be ready for human testing, Reuters Health reports. Italy's National Health Institute has worked on a 'different approach to tackling HIV' for the past five years. Unlike most 'traditional vaccines,' which have focused on trying to bolster www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=2367

2001-01-22

Science & Medicine - U.S. Government Awards $1 Million Grant to British PowderJect Pharmaceuticals for Development of HIV Vaccine The U.S. National Institute of Allergy and Infectious Diseases, in association with the University of Pittsburgh, on Thursday awarded a one-year, $1 million grant to British biotech company PowderJect Pharmaceuticals to help fund the development of a powdered DNA-based HIV vaccine, Reuters reports. Researche www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=7445

2001-10-15

Science & Medicine - Thailand to Host 'World's Biggest' HIV Vaccine Trial The Thai government on Thursday announced that it will begin the 'world's biggest' HIV vaccine trial in December, Agence France-Presse reports. The Thai government, in collaboration with other international groups including the U.S. Military HIV Research Program, the Royal Thai Army Medical Department and th www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=12173

2002-07-08

Science & Medicine - St. Louis University To Begin Trial of Preventive Hepatitis C Vaccine St. Louis University's Center for Vaccine Development is launching the first clinical trial of a hepatitis C vaccine in the United States, the St. Louis Post-Dispatch reports. The trial, which will be conducted in conjunction with Emeryville, Calif.-based biotechnology company Chiron, is the first human tria www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=20914

2003-11-18

Recent Releases - IAVI Report on Global Impact of AIDS Vaccine, Brief on Advanced Market Commitment for Vaccine Development The International AIDS Vaccine Initiative recently released a report and brief discussing different aspects of HIV/AIDS vaccine development. Summaries of two of the resources are below. 'Estimating the Global Impact of an AIDS Vaccine': The publication suggests that an HIV/AIDS vaccine that is only moderatel www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=34171

2005-12-07

Science & Medicine - GSK, Institut Pasteur Collaborate To Develop HIV Vaccine Adapted From Measles Vaccine GlaxoSmithKline and France's Institut Pasteur announced on Monday they are collaborating to develop an experimental HIV vaccine by fusing the virus' genes onto an existing measles vaccine, Reuters reports. Institut Pasteur will license the measles vaccine vector technology to GSK, and researchers from both o www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=33958

2005-11-28